【摘要】：目的:觀察鹿血晶治療腫瘤化療所致血小板減少癥的臨床療效。材料與方法:符合條件的50例患者(1.經(jīng)組織學(xué)或細(xì)胞學(xué)檢查診斷的惡性腫瘤需化療的患者;2.住院患者,經(jīng)一周期化療后血小板降低至(25.0-75.0)×109/L;3.需要繼續(xù)接受至少兩個(gè)周期以上相同化療方案,劑量調(diào)整不超過(guò)±10%;4.男女不限,年齡在18-70歲;5.肝腎功等檢查基本正常;6.ECOG評(píng)分≤2分;7.預(yù)計(jì)生存期大于3個(gè)月。)隨機(jī)分為T(mén)PO組和TPO+鹿血晶組,各25例。TPO組:使用TPO 1.5萬(wàn)U,每日一次,皮下注射,TPO+鹿血晶組:使用TPO 1.5萬(wàn)U,每日一次,皮下注射聯(lián)合鹿血晶1g,每日三次,口服,兩組觀察時(shí)間最長(zhǎng)均為14d,觀察血小板計(jì)數(shù)、白細(xì)胞、紅細(xì)胞、生命體征、中醫(yī)主要癥狀、肝腎功能、凝血功能及經(jīng)濟(jì)費(fèi)用等。結(jié)果:1.兩組臨床療效有差異,統(tǒng)計(jì)學(xué)有意義(P0.05);2.兩組各自治療前后血小板計(jì)數(shù)比較差異統(tǒng)計(jì)學(xué)有意義(P0.05),兩組組間治療前血小板計(jì)數(shù)、治療后血小板計(jì)數(shù)、血小板計(jì)數(shù)持續(xù)50×109/L天數(shù)、血小板恢復(fù)至100×109/L所需天數(shù)對(duì)比差異統(tǒng)計(jì)學(xué)沒(méi)有意義(P0.05);3.TPO組治療前后白細(xì)胞,兩組治療前后紅細(xì)胞、中性粒細(xì)胞對(duì)比統(tǒng)計(jì)學(xué)沒(méi)有意義(P0.05),而TPO+鹿血晶組治療前后白細(xì)胞對(duì)比差異統(tǒng)計(jì)學(xué)有意義(P0.05);4.在中醫(yī)主要癥狀中,兩組在神疲乏力、心悸氣短、睡眠等癥狀對(duì)比差異統(tǒng)計(jì)學(xué)有意義(P0.05),在頭暈?zāi)垦�、納呆食少、腰膝酸軟、自汗盜汗等癥狀對(duì)比差異統(tǒng)計(jì)學(xué)沒(méi)有意義(P0.05);5.所有患者均未發(fā)生明顯的藥物不良反應(yīng)。結(jié)論:鹿血晶聯(lián)合TPO升血小板療效優(yōu)于單藥TPO,并能縮短腫瘤化療所致血小板減少癥的治療時(shí)間,鹿血晶能改善患者神疲乏力、心悸氣短、睡眠等癥狀,且安全性良好。
[Abstract]:Objective: to observe the clinical effect of Luxuejing on thrombocytopenia induced by tumor chemotherapy. Materials and methods: 50 eligible patients (1. 5%). Patients with malignant tumors diagnosed by histology or cytology need chemotherapy. In inpatients, after one cycle of chemotherapy, platelets decreased to (25.0-75.0) 脳 109 / L ~ (3). Need to continue to receive at least two cycles of the same chemotherapy regimen, dose adjustment does not exceed 鹵10 ~ 4. Men and women do not limit, the age of 18 to 70 years old or 5. 6. ECOG score 鈮，

本文編號(hào)：2260271